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Case presentation 
A 40-year-old man with a history of chest pain, nausea, and palpitation was admitted to 
hospital due to hypercalcaemia and renal function exacerbation. On admission the patient’s 
condition revealed signs of dehydration and tachycardia. Moreover, the patient complained of 
painful ribs. Laboratory tests revealed a high calcium level of 3.69 mmol/L, normal 
parathormone (PTH) — 18.4 pg/mL, and vitamin D deficiency — 22.14 ng/mL (Tab. I). 
Serum phosphate, magnesium, potassium, and sodium were within the normal range, and 
there were no acid-base-balance disturbances. Abdominal ultrasound offered no important 
findings. However, low-dose whole-body computed tomography scanning displayed an 
advanced diffused osteolysis in numerous bones (Fig. 1). Additionally, some rib fractures 
were present. Consecutively, further biochemical analyses found mild normocytic anaemia, an 
elevated erythrocyte sedimentation rate of 94 mm and lactate dehydrogenase of 325 U/L, 
monoclonal gammopathy features in protein electrophoresis, and a κ/λ serum ratio equal to 
1696.1.  
The above led to a suspicion of non-PTH-mediated hypercalcaemia (NPTH-H) in the course 
of multiple myeloma (MM). Treatment then included intravenous fluids, forced diuresis, and 
calcitonin and zoledronic acid administered following an improvement of renal function (a 
glomerular filtration rate of 49 mL/min/1.73 m2). Unexpectedly, a severe (0.2 mmol/L) 
hypophosphataemia with hypophosphaturia (< 0.1 mmol/L) occurred four days later. Tubular 
reabsorption of phosphate (TRP) was within the normal range — 0.895 (0.85–0.95), while the 
tubular maximum reabsorption rate of phosphate to glomerular filtration rate (TmP/GFR) 
decreased significantly to 0.19 mmol/L (1.0–1.35). On the other hand, prior to bisphosphate 
administration, these parameters were consecutively 0.52 and 0.43 mmol/L, with phosphate 
concentration 0.82 mmol/L and its excretion in urine at 5.4 mmol/L, together with features of 
mild acute kidney injury (Tab. I). The PTH level increased slightly.  
Despite the patient’s relatively stable state, insufficient oral supplementation of phosphate and 
severity of observed hypophosphataemia accounted for resorting to the application of 
intravenous phosphate infusion, which was continued for four days. Concomitant treatment 
i.a. involved alphacalcidol and cholecalciferol. 
To confirm neoplastic disease, bone marrow biopsy was performed, revealing a level of 
infiltration of pathological plasma cells equal to 42.7%. 
 
Discussion 
Multiple myeloma is a neoplastic disease characterised by lytic lesions of bones [1]. The 
diagnosis is rare in adults under 40 years old (approximately 2%), with average age at 
diagnosis being 70 years. MM-related hypercalcaemia is caused by osteoclast activation 
involving a receptor activator of the NF-κB (RANK) system, as accompanied by hydrogen 
and cytokine release — mainly of interleukin-6, sclerostin, and the glycoprotein Dickkopf-1 
(DKK-1) [2]. Zoledronate therefore serves as a standard treatment because it binds to 
hydroxyapatite complexes at metabolically active sites on bones. It also inhibits the farnesyl 
pathway in neoplastic cells [3].  
Because an extremely advanced osteolysis was present in our patient, usage of zoledronate 
was capable of causing a calcium and phosphate release-block from bones, and this was 
indeed observed. Secondarily to border hypoparathyroidism-PTH suppression and a decrease 
in the calcitriol level, the patient had not saved phosphate prior to the zoledronate therapy. A 
dangerous reduction in phosphate level following bisphosphonate treatment with an increase 
in the TRP value would seem to confirm the association. Unlike with typical findings, we 
noted rare profound hypophosphataemia, seen in just 1% of cases [4]. Given the lack of 
phosphaturia, glycosuria, and tubular loss of other ions, Fanconi syndrome secondary to 
bisphosphonate use was not suspected. Nonetheless, such effects have been described in the 
literature [5]. 
In conclusion, the case presents the NPTH-H treated effectively with bisphosphonate, albeit 
accompanied by severe, life-threatening hypophosphataemia. Thus far, a phenomenon of this 
kind has not gained broad discussion in the literature. Our hypothesis implies that the 
advanced osteolysis and mechanisms adaptive in the event of calcium and phosphate release 
from bones are what trigger the zoledronate effect. Also, despite zoledronate being the 
treatment of choice in hypercalcaemia, significant side effects may occur. It is of great 
importance that the observed relationship be analysed with caution, due to the slight renal 
dysfunction. Ion levels, TRP, vitamin D, and PTH concentrations prior to zoledronate therapy, 
as well as control measurements of both serum and urine phosphate, and calcium levels – with 
the excretion fraction throughout the first post-treatment days – would all then seem to be 
justified. 
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Figure 1. The whole-body CT scan reveals numerous signs of multiple myeloma. A. Axial 
image of the scull shows multiple lytic lesions. B. Sagittal reconstruction over the lumbar 
spine shows signs of osteoporosis – diffuse loss and thickening of the trabeculae in the spine 
and a compression fracture of lumbar vertebra (L1). C. Axial image of the lower extremities 
shows intramedullary soft tissue lesion in the proximal femur (arrow). D. Axial image of the 
chest shows well-circumscribed, lytic bone erosion in the vertebral body (arrow). E. Axial 
image of the chest shows erosion with scalloping of the cortical bone in the rib (arrowhead) 
 
  
Table I. Findings of essential laboratory tests  
Ca — calcium; FE — fraction excretion; Mg — magnesium; P — phosphate; PTH — 
parathormone; TmP/GFR — tubular reabsorption rate of phosphate to glomerular filtration 
rate; TRP — tubular reabsorption of phosphate; UCa — urinary calcium; UP — urinary 
phosphate; ZA — zoledronic acid; athe norm adjusted for patient’s age, according to [6] 
Variable Unit Norm 
Result prior to 
ZA treatment 
Result post ZA 
treatment 
Ca mmol/L 2.15–2.6 3.69 1.91 
UCa mmol/L – 2.7 0.5 
FE Ca – 0.01–0.02 0.064 0.056 
P mmol/L 0.81–1.45 0.82 0.2 
UP mmol/L – 5.4 < 0.1 
P metabolism 
features 
TRP – 0.85–0.95 0.52 0.895 
TmP/GFR mmol/L 1.0–1.35 a 0.43 0.19 
Mg mmol/L 0.7–1.0 0.82 1.14 
PTH pg/mL 15.0–65.0 18.4 30.9 
25-hydroxy-vitamin D3 ng/mL 30.0–80.0 22.14 Not measured 
